Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?

Nav

General Info

Geography

Netherlands (NLD)

Time period covered

01/2001 - 12/2005

Data type

Scientific literature

Keywords

Chemotherapy, Health care costs, Multiple myeloma

Citation

Authors

Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, Uyl-de Groot CA

Journal

Value Health

Volume

Issue

Pages

245-53

Publication year

2014

Suggested citation

Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, Uyl-de Groot CA. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?. Value Health. 2014; 17(2): 245-53.

DOI

10.1016/j.jval.2013.12.009

PMID

24636383

GHDx Entry last modified on: Mar 19, 2021

Header sites

Search form

Main menu

Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?

Nav